Hepatitis C and bleeding disorders in Europe

Open access

Abstract

In the 1980s and 1990s, thousands of people with bleeding disorders (PWBD) across the world were infected with HIV and hepatitis C virus (HCV) through contaminated treatment products. The extent of the infection, as well as the needs of those still living with HCV, were never properly assessed. The purpose of our survey was to identify how many PWBD were infected with HCV in Europe, as well as their health status and needs. HCV infection was defined as any person with a bleeding disorder who was exposed to the virus and seroconverted to become anti-HCV antibody positive. The survey also looked at testing and treatment availability. Between December 2016 and March 2017, the survey was distributed to 45 national patient organisations in the European Haemophilia Consortium (EHC), who were encouraged to respond with the support of a local hepatologist. The data gathered led us to estimate that some 15,000 people with bleeding disorders were infected with HCV in the 30 countries that responded. Although some countries have detailed records of patients with HCV, most - including some with national haemophilia registries - were unable to provide exact numbers of initial infections, HIV coinfection, survival and SVR rates. Responding countries reported varying degrees of monitoring for disease progression, as well as extremely divergent access to new direct-acting antivirals, with only eight countries prioritising PWBD for treatment. With liver disease and hepatocellular carcinoma being among the main causes of death in an aging bleeding disorders population, this survey identifies a clear gap in care. It is a frustrating paradox that today, in many European countries PWBD, such as haemophilia, may live long and productive lives due to much-improved access to factor replacement therapy, yet die prematurely of a curable disease such as hepatitis C. It has been demonstrated that HCV eradication in PWBD can be achieved through national commitment, especially when the patient population is limited and HCV eradication could be achieved in the short-term. The eradication of HCV in PWBD in Europe is an idea whose time has come.

1. Makris M, Konkle BA. Hepatitis C in haemophilia: time for treatment for all. Haemophilia 2017; 23(2): 180-1. doi:

2. Evatt BL. The tragic history of AIDS in the hemophilia population. 1982-1984. J Thromb Haemost 2006; 4(11): 2295-301. doi 10.1111/j.1538-7836.2006.02213.x.

3. O’Mahony B, Noone D, Giangrande PLF, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19(4): e239-47. doi:

4. World Federation of Hemophilia. Report on the Annual GlobalSurvey 2014. 2015. Available from http://www1.wfh.org/publications/files/pdf-1627.pdf (accessed 13 March 2018).

5. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014; 107: 23-30. doi:

6. Persico M, Rosato V, Aglitti A, et al. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. Antivir Ther 2017. doi:

7. El Sherif O, Afhdal N, Curry M. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. J Viral Hepat 2017; 24(10): 808-13. doi:

8. Posthouwer D, Plug I, van der Bom JG, et al. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005; 90(6): 846-50.

9. Health Protection Surveillance Centre, Ireland. National Hepatitis C Database for infection acquired through blood and blood products: 2015 Report. [2015]. Available from https://www.hpsc.ie/a-z/hepatitis/hepatitisc/hepatitiscdatabase/baselineandfollow-upreports/File,15238,en.pdf (accessed 13 March 2018).

10. Lövdahl S, Henriksson KM, Baghaei F, et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia 2013;19(3): 362-9. doi:

11. Posthouwer D, Plug I, van der Bom JG, et al. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005; 11(3): 270-5. doi:

12. Ebeling F, Rasi V, Laitinen H, Krusius T. Viral markers and use of factor products among Finnish patients with bleeding disorders. Haemophilia 2001; 7(1): 42-6.

13. Irish Haemophilia Society celebrates eradication of Hepatitis C among members. Irish Examiner 22 December 2016. Available from https://www.irishexaminer.com/breakingnews/ireland/irish-haemophilia-society-celebrates-eradicationof-hepatitis-c-among-members-769660.html (accessed 13 March 2018).

14. Cortez-Pinto H. National HCV programmes: a European approach to eliminating hepatitis C. Presentation delivered at the European Haemophilia Consortium Round Table of Stakeholders: HCV and Haemophilia, Brussels, June 2016. Available from https://static.ehc.eu/wp-content/uploads/09-EHC-June-RT-Presentation-Cortez-Pinto-FORDISTRIBUTION.pdf (accessed 14 May 2018).

15. Graham K. Portugal agrees to treat 13,000 Hepatitis C sufferers for free. Digital Journal 8 Feb 2015. Available from http://www.digitaljournal.com/life/health/portugal-agreesto-treat-13-000-hepatitis-c-sufferers-for-free/article/425590 (accessed 13 March 2018).

16. Giangrande PLF, Peyvandi F, O’Mahony B, et al. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 2017; 23(3): 370-5. doi:

17. Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers. Ann Intern Med 2017; 167(5): 311-8. doi:

18. Nyalakonda H, Utay NS. A new era of therapy for hepatitis C virus infection. Curr Opin Infect Di. 2015; 28(5): 471-8. doi:

19. Cousins S. The Tasmanian Hep C Buyers’ Club. New York Times 25 July 2017. Available from https://www.nytimes.com/2017/07/25/opinion/the-tasmanian-hep-c-buyers-club.html (accessed 13 March 2018).

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 110 110 77
PDF Downloads 52 52 39